Pharmaceutical research and development (R&D) is unlikely to be significantly impacted by most favored nation (MFN) pricing, according to industry experts. The US bears the highest drug costs globally ...

Ahead of WTO's 14th ministerial meet, the USTR has called for a rethink of the MFN principle, citing changing economic ...

Peter Rubin discusses how effective President Trump’s executive order could actually be against the factors that dictate drug pricing. Peter Rubin, executive director of No Patient Left Behind, spoke ...

The largest holder of Yellow Corp. shares has asked the company’s directors to fill two vacant board seats and set up a special pay plan to keep around executives and others to sell off assets under ...

Earlier this year, when the administration proposed deep cuts to the National Institutes of Health, lawmakers from both parties swiftly and rightly pushed back. Slashing medical research funding, they ...